Product Details

Artesunate + Sulfadoxine + Pyrimethamine Tablets BP 625 mg deliver a high-quality combination therapy that meets British Pharmacopoeia (BP) standards. This fixed-dose triple combination manages uncomplicated Plasmodium falciparum malaria, combining fast-acting artemisinin action with long-acting antifolate protection in a single uncoated tablet.

The tablets combine:

• Artesunate, an artemisinin derivative that rapidly reduces parasite biomass by generating free radicals that damage the malaria parasite’s membrane structures,
• Sulfadoxine, a sulfonamide antifolate that inhibits parasite folic acid synthesis by blocking dihydropteroate synthase, and
• Pyrimethamine, a dihydrofolate reductase inhibitor that works synergistically with Sulfadoxine to block a second step in parasite folate synthesis, together providing extended antimalarial protection.

Doctors and health programs commonly prescribe this combination as an artemisinin-based combination therapy (ACT) for uncomplicated falciparum malaria, particularly in regions with chloroquine-resistant strains. Hospitals, clinics, and pharmacies rely on this formulation for its consistent quality and dependable therapeutic results. Our manufacturing process follows strict quality standards to guarantee high purity, accurate dosing, and reliable therapeutic efficacy in every batch.

Key Features

• BP-standard compliant triple combination therapy
• Treats uncomplicated Plasmodium falciparum malaria
• Delivers fast-acting artemisinin plus long-acting antifolate action
• Contains Artesunate 100 mg + Sulfadoxine 500 mg + Pyrimethamine 25 mg per tablet
• Maintains a high-purity, stable formulation
• Uses hygienic blister packaging for safe storage
• Suits hospital, clinical, and pharmacy use